Results 221 to 230 of about 160,552 (312)
Immunodeficiency Diseases and Tumor Immunobiology [PDF]
Abramoff, Peter A., Duquesnoy, Rene J.
core +1 more source
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery ...
Jens Tidemandsen +9 more
wiley +1 more source
Effect and Threshold of Endoscopic Findings for CRS Control Status and Long‐Term Outcome Prediction
ABSTRACT Background EPOS 2020 defined chronic rhinosinusitis (CRS) disease control using patient symptoms and medication usage but endoscopic findings were considered optional. The effect of adding endoscopic features, an appropriate threshold, and their association with present or future symptom control have not been studied.
Steven Chun‐Kang Liao +14 more
wiley +1 more source
Co-occurrence of Alpha-1 Antitrypsin Deficiency (AATD) and Common Variable Immunodeficiency (CVID): A Case Report. [PDF]
Aynaci A +4 more
europepmc +1 more source
ABSTRACT Background Pseudomonas aeruginosa is an opportunistic pathogen in cystic fibrosis‐related chronic rhinosinusitis (CF‐CRS) that produces phenazine metabolites pyocyanin and 1‐hydroxyphenazine (1‐HP), which may have detrimental effects on mitochondria, reactive oxygen species (ROS), Ca2+ signaling, and apoptosis.
Joel C. Thompson +8 more
wiley +1 more source
Oral Immunotherapy-Induced Changes in IgE, IgG, and IgA: A Review of Antibody Isotype Shifts and Their Clinical Relevance in Food Allergy. [PDF]
Lasagni G +7 more
europepmc +1 more source
Cryohydrocytosis: When Cold Breaks the Membrane
American Journal of Hematology, EarlyView.
Athina Ntoumaziou +5 more
wiley +1 more source
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol +14 more
wiley +1 more source
Executive Summary: State-of-the-Art Review: Antibiotic Allergy-A Multidisciplinary Approach to Delabeling. [PDF]
Mitri EA +6 more
europepmc +1 more source

